Intercept Pharmaceuticals settles Ocaliva patent litigation case with Dr Reddy#39;s

"Under the terms of the agreement, Intercept granted Dr. Reddy#39;s a non-exclusive, non-sublicensable, non-transferable, royalty-free licence to commercialise its generic version of Ocaliva in the United States commencing on October 26, 2035, or earlier under certain circumstances," Intercept Pharmaceuticals in a regulatory filing said.

from Moneycontrol Business News https://ift.tt/iWF6oZw